Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...
Shanghai MicroPort’s Minos Stent Graft Secures Egyptian Marketing Approval
China’s Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced that it has received...
Sino Biopharmaceutical’s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has...
Porton Pharma Partners with Tong Eye on iPSC-Derived RPE Cell Therapies for Ophthalmic Diseases
Chinese CDMO leader Porton Pharma Solutions Ltd. has entered into a strategic partnership with domestic...
InnoCare Pharma Doses First Patient in Phase II/III Trial of TYK2 Inhibitor for Vitiligo
Chinese biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has administered the first patient dose in...
Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress
Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Market Challenges
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard...
BMS Receives EC Approval for Opdivo-based Perioperative Regimen in NSCLC
Bristol-Myers Squibb (BMS; NYSE: BMY) announced last week that it has received marketing authorization from...
Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial
US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...
China’s AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its...
FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma
The US Food and Drug Administration (FDA) announced this week an indication extension approval for...
Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...
Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...
Hainan Haiyao and Elken Global Form Five-Year Strategic Partnership in Wellness Products
China-based Hainan Haiyao Co., Ltd. (SHE: 000566) has entered into a five-year strategic collaboration agreement...
Beijing Balance Medical’s Renato System Gets NMPA Approval for Valve-in-Valve Therapy
China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has obtained market authorization from China’s...
North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine
China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...
Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss
South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration...
Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth
Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY)...
CanSino Biologics Gets Indonesian Approval for Phase I Trial of Inhalable Tuberculosis Vaccine
China-based CanSino Biologics Inc. (HKG: 6185), a specialist in vaccine development, has announced that it...
Haisco Pharma’s HSK21542 Approved by NMPA for Post-Abdominal Surgery Pain
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...